Key Highlights
- Immutep shares surged more than 101% following the FDA’s Orphan Drug Designation for eftilagimod alfa (efti) in soft tissue sarcoma treatment.
- Orphan Drug status applies to rare cancers affecting under 200,000 Americans annually.
- The designation provides significant advantages: seven-year market exclusivity, tax incentives, waived fees, and enhanced FDA guidance.
- Supporting evidence comes from the EFTISARC-NEO Phase II clinical trial, which successfully achieved its primary objective in 38 participants.
- The announcement arrives after Immutep discontinued its TACTI-004 Phase III study, a move projected to conserve cash resources through Q2 2027 and beyond.
Shares of Immutep experienced remarkable growth on Wednesday, more than doubling in value after the Australian biopharmaceutical company secured Orphan Drug Designation from the U.S. Food and Drug Administration for eftilagimod alfa, its primary cancer therapeutic candidate.
The Australia-based biotechnology firm witnessed its share price surge 101.3% to reach A$0.079 throughout Wednesday’s trading session.
The regulatory designation encompasses the application of efti for treating soft tissue sarcoma (STS), a rare malignancy representing a significant area of unmet clinical demand across the United States.
Obtaining Orphan Drug Designation delivers substantial benefits to pharmaceutical developers: comprehensive regulatory assistance, eligibility for tax incentives, exemption from various administrative fees, and crucially, seven years of marketplace exclusivity upon final approval.
The FDA’s determination relied on clinical evidence from the EFTISARC-NEO Phase II clinical investigation. This research evaluated efti alongside radiotherapy treatment and Merck’s KEYTRUDA (pembrolizumab) in patients diagnosed with surgically resectable soft tissue sarcoma prior to operative intervention.
Among 38 assessable participants, the clinical trial successfully achieved its primary objective. Researchers documented a median tumour hyalinization/fibrosis percentage of 51.5%, substantially exceeding the predetermined threshold of 35% and dramatically outperforming the historical standard of approximately 15% associated with radiotherapy as a standalone treatment.
Positive outcomes were observed across various sarcoma classifications. The treatment demonstrated a favourable safety profile, with no reported postponements of scheduled surgical procedures.
TACTI-004 Trial Discontinuation
This encouraging regulatory development follows closely behind Immutep’s decision to discontinue its TACTI-004 Phase III clinical trial in early March. That investigation was evaluating efti as a first-line treatment option for non-small cell lung cancer patients.
An Independent Data Monitoring Committee advised terminating the study based on futility findings. The organization is currently executing an organized wind-down of TACTI-004 operations.
Immutep indicated that concluding the trial should significantly extend its financial resources well past the previously anticipated Q2 2027 timeframe.
Development Portfolio and Financial Position
Apart from soft tissue sarcoma and lung cancer applications, Immutep maintains five active LAG-3-focused development programs. Among these initiatives, IMP761 is presently undergoing Phase I evaluation for autoimmune condition treatments.
The organization reported a net financial loss of A$61.4 million for fiscal year 2025, representing an increase from the A$42.7 million deficit recorded in 2024.
As a pre-revenue biotechnology enterprise, Immutep continues to require additional capital infusions to support ongoing research activities and product development initiatives.
The company has established strategic collaborations with leading pharmaceutical corporations, including Merck (MSD), to facilitate advancement of its therapeutic pipeline.
The EFTISARC-NEO clinical trial results, which provided the foundation for Wednesday’s FDA designation, incorporated translational research findings aligned with efti’s biological mechanism of action — immune system activation through LAG-3 pathway modulation.
